Noctamid (Lormetazepam)

Lormetazepam binds to the benzodiazepine site on the GABA‑A receptor, enhancing the inhibitory action of GABA. This increases chloride ion flow into neurons, hyperpolarising them and decreasing neuronal excitability, which produces a calming, sedative effect that facilitates sleep.

The appropriate dose of Noctamid is determined by the prescribing clinician based on the patient’s age, medical condition, and response to therapy. Dosage instructions are individualized and should be followed exactly as written on the prescription label.

Safety of lormetazepam in pregnancy or lactation has not been fully established. It is generally advised to avoid use unless the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Noctamid, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with non‑benzodiazepine hypnotics (e.g., zolpidem), lormetazepam has a longer half‑life and a higher potential for residual daytime sedation and dependence. However, it may be preferred in patients who require a well‑studied benzodiazepine with predictable pharmacokinetics for short‑term use.

Noctamid tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and do not use after the expiry date printed on the package.

Noctamid is taken orally, usually once nightly, shortly before bedtime. The tablet should be swallowed whole with a glass of water and not chewed or crushed. Patients should follow the exact timing and dosage prescribed by their clinician.

The most serious risks include respiratory depression, especially when combined with other depressants, development of physical dependence, withdrawal seizures upon abrupt discontinuation after prolonged use, and rare severe allergic reactions. Patients should be monitored closely for these events.

Noctamid is contraindicated in individuals with known hypersensitivity to lormetazepam or other benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and in patients who are currently abusing alcohol or other central nervous system depressants. It should also be used with caution in the elderly.